Review
Copyright ©2011 Baishideng Publishing Group Co.
World J Clin Oncol. Jun 10, 2011; 2(6): 262-271
Published online Jun 10, 2011. doi: 10.5306/wjco.v2.i6.262
Table 1 Efficacy (progression-free survival) outcomes of trials in the maintenance setting in patients with non small cell lung carcinoma
TrialTreatmentnMedian PFS (mo)HR
AVAiL[31]Placebo413.2NR
Bevacizumab 7.5 mg/kg1744.6
Bevacizumab 15 mg/kg1624.6
ATLAS[32]Bevacizumab + erlotinib3704.760.722
Bevacizumab + placebo3733.75P = 0.0012
SATURN[33]Erlotinib437NR0.71
Placebo447NRP < 0.0001
JMEN[30]Pemetrexed4414.00.5
Placebo2222.0P < 0.0001